Results 221 to 230 of about 338,947 (383)

Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate‐to‐Severe Atopic Dermatitis

open access: yesAllergy, EarlyView.
Data were included from adolescents with moderate‐to‐severe AD treated with the JAK1 inhibitor abrocitinib (200 mg/100 mg) across JADE clinical trials. Improvements in skin clearance (per EASI‐75) and itch (per PP‐NRS4) were maintained for up to 112 weeks with both abrocitinib doses.
Amy S. Paller   +13 more
wiley   +1 more source

Atopic dermatitis: Influence of bacterial infections on human monocyte and neutrophil granulocyte functional activities

open access: bronze, 1988
Ulrich Mrowietz   +4 more
openalex   +1 more source

Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study [PDF]

open access: green, 1994
TH. JOOST   +5 more
openalex   +1 more source

Methotrexate in the treatment of atopic dermatitis. [PDF]

open access: yesPostepy Dermatol Alergol
Nowicki RJ   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy